Search results
Results from the WOW.Com Content Network
Diversion Investigator (DI) is the title of a specialist position within the Drug Enforcement Administration (DEA) of the United States Department of Justice.DIs are responsible for addressing the problem of diversion of controlled pharmaceuticals and regulated chemicals from the legitimate channels in which they are manufactured, distributed, and dispensed.
Under the CSA, the DEA must begin investigating the rescheduling of a drug after receiving a petition by from any interested party, including the manufacturer of a drug, a medical society or association, a pharmacy association, a public interest group concerned with drug abuse, a state or local government agency, or an individual citizen.
The United States Drug Enforcement Administration (DEA) maintains lists regarding the classification of illicit drugs (see DEA Schedules).It also maintains List I of chemicals and List II of chemicals, which contain chemicals that are used to manufacture the controlled substances/illicit drugs.
Controlled Substances; Long title: An Act to amend the Public Health Service Act and other laws to provide increased research into, and prevention of, drug abuse and drug dependence; to provide for treatment and rehabilitation of drug abusers and drug dependent persons; and to strengthen existing law enforcement authority in the field of drug abuse.
The Drug Enforcement Administration was established on July 1, 1973, [4] by Reorganization Plan No. 2 of 1973, signed by President Richard Nixon on July 28. [5] It proposed the creation of a single federal agency to enforce the federal drug laws as well as consolidate and coordinate the government's drug control activities.
A DEA number (DEA Registration Number) is an identifier assigned to a health care provider (such as a physician, physician assistant, nurse practitioner, optometrist, podiatrist, dentist, or veterinarian) by the United States Drug Enforcement Administration allowing them to write prescriptions for controlled substances.
Another small study from 2011 examined 15 men with male pattern baldness. The men used a topical hair loss treatment called NuH Hair, which combined finasteride, dutasteride, and minoxidil.
The positive results of the study led to the inclusion of heroin-assisted treatment into the services of the mandatory health insurance in 2009. In 2017, Germany re-allowed medical cannabis; after the 2021 German federal election , the new government announced in their coalition agreement their intention to legalise cannabis for all other ...